Effects of aging and liver disease upon the pharmacokinetics of nipradilol

Clinical Drug Investigation

Volumn 16, Issue 3, 1998, Pages 251-257

  Aramaki, Takumi ^a   Katsuta, Yasumi ^a   Sekiyama, Tatsuya ^a   Tsutsui, Hitoshi ^a   Kome Ichi, Hirokazu ^a   Ohsuga, Masaru ^a   Satomura, Katsuaki ^b   Yoshimura, Mitsuo ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KOWA COMPANY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NIPRADILOL;

ADULT; AGING; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031714675     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816030-00009     Document Type: Article

References (16)

1. Uchida Y, Nakamura M, Tsuruta T, et al. Nipradilol. In: Scriabinc A, editor. New cardiovascular drugs. New York: Raven Press, 1987: 45-115
2. Uchida Y, Nakamura M, Shimizu S, et al. Vasoactive and β-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch Int Pharmacodyn Ther 1983; 262: 132-49
3. Fuzii M, Shirasawa Y, Kondo S, et al. Cardiovascular effects of nipradilol, a β-adrenoceptor blocker with vasodilating properties. Jpn Heart J 1986; 27 (2): 233-50
4. Aramaki T, Sekiyama T, Katsuta Y, et al. Long-term haemodynamic effects of a 4 week regimen of nipradilol, a new β-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis: a comparative study with propranolol. J Hepatology 1992; 15: 48-53
5. Okamura H, Aoyagi T, Iwamura K, et al. Effect of long-term therapy with nipradilol on oesophageal varices in patients with compensated cirrhosis. Results of a multicenter open study. Arzneimittel Forschung 1994; 44 (11): 1250-4
6. Ohsuga M, Cailmail S, Lebrec D. Hemodynamic effects of nipradilol, a new β-adrenergic antagonist combined with a nitroxy base, in rats with intra-or extra-hepatic portal hypertension. J Hepatol 1993; 17: 236-40
7. Yoshimura M, Kozima J, Itoh A, et al. Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent, in humans. Jpn J Clin Pharmacol Ther 1985; 16 (4): 679-91
8. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8): 646-9
9. Yoshimura M, Kojima J, Itoh T, et al. Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. I. Studies on interspecies variation in laboratory animals. J Pharmacobiodyn 1985; 8: 738-50
10. Greenblatt DJ, Divoll M, Abernethy DR, et al. Physiologic changes in old age: relation to altered drug disposition. J Am Geriatr Soc 1982; 30 (11) Suppl. S6-10
11. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321 (5): 303-9
12. Yoneda M, Ohkawa Y, Muramatsu T. Physicochemical properties and stabilities of nipradilol (K-351) [in Japanese]. Iyakuhin Kenkyu 1985; 16: 1100-11
13. Feely J, Wilkinson GR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 1981; 304 (12): 692-5
14. Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the deposition and elimination of diazepam in adult man. J Clin Invest 1975; 55: 347-59
15. Tateishi T, Fujimura A, Shiga T, et al. Influence of aging on the oxidative and conjugative metabolism of propranolol. Jpn J Clin Pharmacol Ther 1993; 24 (2): 419-24
16. Kohayashi A, Katsuta Y, Aramaki T, et al. Interrelation between esophageal varices and systemic and hepatic hemodynamics in male patients with compensated cirrhosis. Jpn J Med 1991; 30 (4): 318-25